gip glp 1 glucagon agonists Frontiers Glucagon-Like Peptide-1 (GLP-1) & Gastric

Rahmatinejad FZ, Kharat H, Jalili MK, Renani H, Mobasheri

The Source Data files contain the minimum dataset required to interpret, verify, and extend the findings reported in this study

Discussion In this study of 606 434 people (protocol 1 and protocol 2 combined) evaluating both treatment initiation and treatment adherence effects over a median of three yearstotalling 1 559 238 person years, GLP-1 receptor agonist use (versus SGLT-2 inhibitor use) was consistently associated with a reduced risk of developing various SUDs, including disorders related to alcohol use, cannabis use, cocaine use, nicotine use, and opioids use, and other SUDs

Should I follow any restrictions related to diet